OBJECTIVE: To evaluate safety and antiinflammatory efficacy of placing two Surodex (Oculex Pharmaceuticals, Inc., Sunnyvale, CA) in the eye after @entity231 surgery in comparison with @entity134 eyedrops and to compare anterior versus posterior chamber placement. DESIGN: Randomized, masked, controlled trial. @entity1 : One hundred four eyes of 104 Asian @entity1 undergoing extracapsular @entity231 extraction with intraocular lens implantation were examined. Of these, 33 eyes of 33 @entity1 served as control eyes (group A). INTERVENTION: Two Surodex pellets were inserted in the anterior chamber (AC) of 35 eyes (group B), and two Surodex pellets were inserted in the ciliary sulcus of 36 eyes (group C) at the conclusion of surgery. Control eyes received neither Surodex nor a placebo implant, but were prescribed conventional 0.1% @entity619 eyedrops four times daily for 4 weeks. MAIN OUTCOME MEASURES: Anterior chamber flare and cells were graded clinically at the slit lamp. Anterior chamber flare was assessed objectively with the Kowa FC500 Laser Flare Meter (Kowa Co. Ltd, Tokyo, Japan). Intraocular pressure and corneal endothelial specular microscopy with morphometric cell analysis were performed for up to 1 year after surgery. RESULTS: Lower flare meter readings occurred in both Surodex groups at all postoperative visits, as compared with the @entity619 eyedrop group, with statistical significance at days 4 (P = 0.001), 8 (P = 0.001), and 15 (P = 0.02). No difference in flare occurred between AC and ciliary sulcus placement. Clinical slit-lamp assessment of anterior chamber flare and cells showed no difference between @entity735 and @entity619 -treated eyes. Nine of 33 eyes (27.3%) in group A required @entity134 augmentation, as opposed to 4 of 71 eyes (5.6%) in groups B and C. Inflammatory symptoms were reduced in the @entity735 , with statistical significance for @entity2194 (P = 0.001), @entity3917 (P = 0.04), and lacrimation (P = 0.01). No complications occurred with @entity735 , and no significant difference in endothelial cell loss was noted between @entity735 and @entity619 -treated eyes up to 1 year after surgery. CONCLUSIONS: Intraocular placement of two Surodex is a safe and effective treatment method to reduce @entity32 after @entity231 surgery and clearly is superior to eyedrops in reducing inflammatory symptoms and aqueous flare as measured with the laser flare meter. No difference in efficacy between AC placement and ciliary sulcus placement of Surodex was detected in this study.

Randomized clinical trial of Surodex @entity134 drug delivery system for XXXX surgery: anterior versus posterior placement of two Surodex in the eye.

@entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS'] @entity32 :: ('MESH:D007249', 'Disease') :: ['intraocular inflammation'] @entity2194 :: ('MESH:D005128', 'Disease') :: ['ocular discomfort'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity735 :: ('MESH:D005124', 'Disease') :: ['Surodex-treated eyes'] @entity3917 :: ('MESH:D020795', 'Disease') :: ['photophobia']
@entity231 :: (MESH:D002386,Disease) :: ['cataract']
